CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade VYNE Therapeutics Inc. - VYNE CFD

    2.23
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Vyne Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.23
    Open* 2.19
    1-Year Change* -29.58%
    Day's Range* 2.19 - 2.28
    52 wk Range 1.81-8.73
    Average Volume (10 days) 249.01K
    Average Volume (3 months) 8.77M
    Market Cap 26.10M
    P/E Ratio -100.00K
    Shares Outstanding 13.96M
    Revenue 354.00K
    EPS -9.05
    Dividend (Yield %) N/A
    Beta 1.19
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 18, 2024 2.23 -0.09 -3.88% 2.32 2.37 2.19
    Apr 17, 2024 2.35 -0.02 -0.84% 2.37 2.44 2.35
    Apr 16, 2024 2.40 0.00 0.00% 2.40 2.43 2.35
    Apr 15, 2024 2.51 -0.21 -7.72% 2.72 2.72 2.37
    Apr 12, 2024 2.75 -0.05 -1.79% 2.80 2.83 2.64
    Apr 11, 2024 2.95 0.43 17.06% 2.52 2.95 2.52
    Apr 10, 2024 2.63 -0.04 -1.50% 2.67 2.80 2.56
    Apr 9, 2024 2.71 0.03 1.12% 2.68 2.73 2.67
    Apr 8, 2024 2.68 -0.07 -2.55% 2.75 2.78 2.59
    Apr 5, 2024 2.78 -0.05 -1.77% 2.83 2.88 2.73
    Apr 4, 2024 2.82 -0.21 -6.93% 3.03 3.07 2.76
    Apr 3, 2024 3.05 0.11 3.74% 2.94 3.05 2.94
    Apr 2, 2024 2.97 0.01 0.34% 2.96 3.03 2.88
    Apr 1, 2024 3.03 -0.04 -1.30% 3.07 3.12 2.93
    Mar 28, 2024 3.03 0.10 3.41% 2.93 3.06 2.84
    Mar 27, 2024 2.91 0.08 2.83% 2.83 3.03 2.72
    Mar 26, 2024 2.76 0.30 12.20% 2.46 2.77 2.40
    Mar 25, 2024 2.70 0.35 14.89% 2.35 3.09 2.35
    Mar 22, 2024 2.35 0.11 4.91% 2.24 2.37 2.17
    Mar 21, 2024 2.27 0.16 7.58% 2.11 2.27 2.07

    VYNE Therapeutics Inc. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 Vyne Therapeutics Inc Earnings Release
    Q1 2024 Vyne Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, August 12, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q2 2024 Vyne Therapeutics Inc Earnings Release
    Q2 2024 Vyne Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.477 0.931 20.993 0 10.64
    Revenue 0.477 0.931 20.993 0 10.64
    Total Operating Expense 34.772 39.842 273.539 76.242 65.175
    Selling/General/Admin. Expenses, Total 16.387 20.299 89.543 22.481 12.186
    Research & Development 18.385 19.543 43.533 53.761 52.989
    Operating Income -34.295 -38.911 -252.546 -76.242 -54.535
    Interest Income (Expense), Net Non-Operating 0 -5.61 -4.39 2.539 3.09
    Net Income Before Taxes -33.932 -44.656 -255.826 -73.703 -51.445
    Net Income After Taxes -33.945 -44.208 -255.568 -73.703 -51.445
    Net Income Before Extra. Items -33.945 -44.208 -255.568 -73.703 -51.445
    Net Income -23.21 -73.329 -255.568 -73.703 -51.445
    Income Available to Common Excl. Extra. Items -33.945 -44.208 -255.568 -73.703 -51.445
    Income Available to Common Incl. Extra. Items -23.21 -73.329 -255.568 -73.703 -51.445
    Diluted Net Income -23.21 -73.329 -255.568 -73.703 -51.445
    Diluted Weighted Average Shares 3.186 2.859 1.80114 0.33084 0.30098
    Diluted EPS Excluding Extraordinary Items -10.6544 -15.4628 -141.892 -222.774 -170.926
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -10.6544 -15.4628 -141.892 -222.774 -170.926
    Total Extraordinary Items 10.735 -29.121
    Cost of Revenue, Total 1.392
    Gross Profit 19.601
    Other Operating Expenses, Total 139.071
    Other, Net 0.363 -0.135 1.11
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.135 0.099 0.006 0.167 0.126
    Revenue 0.135 0.099 0.006 0.167 0.126
    Total Operating Expense 10.453 5.974 7.99 9.5 8.413
    Selling/General/Admin. Expenses, Total 3.22 3.24 3.711 3.954 4.305
    Research & Development 7.233 2.734 4.279 5.546 4.108
    Operating Income -10.318 -5.875 -7.984 -9.333 -8.287
    Interest Income (Expense), Net Non-Operating 0 0 0
    Other, Net 0.28 0.263 0.236 0.078 0.052
    Net Income Before Taxes -10.038 -5.612 -7.748 -9.255 -8.235
    Net Income After Taxes -10.038 -5.612 -7.761 -9.255 -8.235
    Net Income Before Extra. Items -10.038 -5.612 -7.761 -9.255 -8.235
    Total Extraordinary Items -0.02 -0.01 -2.184 -0.204 -0.241
    Net Income -10.058 -5.622 -9.945 -9.459 -8.476
    Income Available to Common Excl. Extra. Items -10.038 -5.612 -7.761 -9.255 -8.235
    Income Available to Common Incl. Extra. Items -10.058 -5.622 -9.945 -9.459 -8.476
    Diluted Net Income -10.058 -5.622 -9.945 -9.459 -8.476
    Diluted Weighted Average Shares 3.274 3.255 3.2245 3.21833 3.21859
    Diluted EPS Excluding Extraordinary Items -3.06597 -1.72412 -2.40688 -2.87571 -2.55857
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -3.06597 -1.72412 -2.40688 -2.87571 -2.55857
    Cost of Revenue, Total
    Gross Profit
    Other Operating Expenses, Total
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 38.275 63.186 87.259 76.414 139.5
    Cash and Short Term Investments 30.908 42.25 57.563 55.861 136.25
    Cash & Equivalents 30.908 42.25 57.563 43.759 49.51
    Short Term Investments 12.102 86.74
    Prepaid Expenses 2.127 5.119 4.591 1.557 3.25
    Total Assets 40.758 67.046 93.742 81.159 139.928
    Property/Plant/Equipment, Total - Net 0 0.354 2.138 4.579 0.146
    Long Term Investments 0
    Other Long Term Assets, Total 2.483 3.506 4.345 0.166 0.282
    Total Current Liabilities 9.345 18.41 21.765 29.326 9.544
    Accounts Payable 2.386 6.51 4.78 19.352 3.29
    Accrued Expenses 4.381 8.942 12.209 4.473 5.998
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.578 2.958 4.776 5.501 0.256
    Total Liabilities 9.345 18.41 56.249 63.584 9.551
    Total Long Term Debt 0 0 33.174 32.725 0
    Other Liabilities, Total 0 1.31 1.533 0.007
    Total Equity 31.413 48.636 37.493 17.575 130.377
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 0 0.005 0.004 0.003 0.003
    Additional Paid-In Capital 693.937 688.156 603.685 328.154 241.106
    Retained Earnings (Accumulated Deficit) -662.735 -639.525 -566.196 -310.587 -110.636
    Unrealized Gain (Loss) 0 0 0.005 -0.096
    Total Liabilities & Shareholders’ Equity 40.758 67.046 93.742 81.159 139.928
    Total Common Shares Outstanding 3.2297 2.97678 2.40048 0.50671 0.32271
    Total Receivables, Net 5.173 7.583 15.819 0.135 0
    Accounts Receivable - Trade, Net 0.173 7.583 15.819 0.135 0
    Redeemable Preferred Stock 0.211
    Total Inventory 7.291 7.404 1.356
    Other Current Assets, Total 0.067 0.943 1.882 17.505
    Goodwill, Net 0
    Long Term Debt 0 33.174 32.725
    Property/Plant/Equipment, Total - Gross 0.905 2.581
    Accumulated Depreciation, Total -0.551 -0.443
    Total Preferred Shares Outstanding 0.003
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 17.511 22.959 33.022 38.275 44.046
    Cash and Short Term Investments 15.448 20.634 30.213 30.908 35.51
    Cash & Equivalents 15.448 20.634 30.213 30.908 35.51
    Total Receivables, Net 0.25 0.234 0.105 5.173 5.471
    Accounts Receivable - Trade, Net 0.25 0.234 0.105 0.173 0.471
    Total Inventory
    Prepaid Expenses 1.759 2.024 2.637 2.127 2.998
    Other Current Assets, Total 0.054 0.067 0.067 0.067 0.067
    Total Assets 19.267 24.959 35.263 40.758 46.908
    Property/Plant/Equipment, Total - Net 0 0.127
    Other Long Term Assets, Total 1.756 2 2.241 2.483 2.735
    Total Current Liabilities 6.449 6.374 7.519 9.345 6.839
    Accounts Payable 0.716 1.159 2.214 2.386 2.523
    Accrued Expenses 4.452 4.379 4.189 4.381 2.164
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.281 0.836 1.116 2.578 2.152
    Total Liabilities 7.762 7.687 8.832 9.345 6.839
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Other Liabilities, Total 1.313 1.313 1.313
    Total Equity 11.505 17.272 26.431 31.413 40.069
    Common Stock 0.00033 0 0 0 0.006
    Additional Paid-In Capital 696.653 695.836 694.937 693.937 692.853
    Retained Earnings (Accumulated Deficit) -685.148 -678.564 -668.506 -662.735 -652.79
    Total Liabilities & Shareholders’ Equity 19.267 24.959 35.263 40.758 46.908
    Total Common Shares Outstanding 3.30478 3.28248 3.27128 3.2297 3.22447
    Current Port. of LT Debt/Capital Leases
    Unrealized Gain (Loss)
    Redeemable Preferred Stock 0 0 0 0.211
    Total Preferred Shares Outstanding 0 0 0
    Other Equity, Total -0.00033
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -23.21 -73.329 -255.568 -73.703 -51.445
    Cash From Operating Activities -29.2 -56.367 -137.082 -65.101 -52.733
    Cash From Operating Activities 0.072 0.109 0.341 0.056 0.022
    Non-Cash Items -8.339 12.077 158.476 6.654 2.864
    Changes in Working Capital 2.277 4.776 -40.331 1.892 -4.174
    Cash From Investing Activities 15.667 1.027 89.107 41.374 -33.876
    Capital Expenditures 0 -0.113 -0.011 -0.14
    Other Investing Cash Flow Items, Total 15.667 1.027 89.22 41.385 -33.736
    Cash From Financing Activities 1.653 39.777 61.808 4.994 125.913
    Financing Cash Flow Items 0 -0.294 -0.141 0 0
    Issuance (Retirement) of Stock, Net 1.653 76.503 61.949 4.994 125.913
    Net Change in Cash -11.88 -15.563 13.834 -18.733 39.304
    Cash Interest Paid 0 2.385 3.941
    Issuance (Retirement) of Debt, Net 0 -36.432 0
    Foreign Exchange Effects 0 0.001
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -5.622 -23.21 -13.265 -3.806 4.67
    Cash From Operating Activities -5.478 -29.2 -25.325 -18.2 -9.039
    Cash From Operating Activities 0 0.072 0.227 0.056 0.044
    Non-Cash Items 0.856 -8.339 -9.686 -10.899 -12.102
    Cash Interest Paid 0 0 0
    Changes in Working Capital -0.712 2.277 -2.601 -3.551 -1.651
    Cash From Investing Activities 5 15.667 16.602 16.688 15.752
    Capital Expenditures
    Other Investing Cash Flow Items, Total 5 15.667 16.602 16.688 15.752
    Cash From Financing Activities -0.217 1.653 1.445 1.471 1.532
    Issuance (Retirement) of Stock, Net -0.217 1.653 1.445 1.471 1.532
    Foreign Exchange Effects
    Net Change in Cash -0.695 -11.88 -7.278 -0.041 8.245
    Issuance (Retirement) of Debt, Net 0 0
    Financing Cash Flow Items 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    VYNE Therapeutics Inc. Company profile

    VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
    Industry: Pharmaceuticals (NEC)

    685 Route 202/206, Suite 301A
    BRIDGEWATER
    NEW JERSEY 08807
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    ETH/USD

    3,085.21 Price
    +0.460% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    XRP/USD

    0.51 Price
    +1.020% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    Gold

    2,392.09 Price
    +0.540% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 21:00 (UTC)
    Spread 0.40

    US100

    17,037.80 Price
    -1.980% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading